ConductScience.org, home

Paper28480503

Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.

Checchio T and 11 others. Clin Pharmacol Ther, 2017. Cited by 21 papers, by iCite.

Cite this record

ConductScience Library. Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis. Papers, record 28480503. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28480503

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2017
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
0.93
iCite
Revised in PubMed
2025-06-23
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Checchio TT
2Ahadieh SS
3Gupta PP
4Mandema JJ
5Puig LL
6Wolk RR
7Valdez HH
8Tan HH
9Krishnaswami SS
10Tallman AA
11Kaur MM
12Ito KK

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Models, StatisticalMajor topic
PiperidinesMajor topic
Protein Kinase InhibitorsMajor topic
PsoriasisMajor topic
PyrimidinesMajor topic
PyrrolesMajor topic
Dose-Response Relationship, Drug
Humans
Severity of Illness Index
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112111919Quantifying heterogeneity in a meta-analysis.Stat Med2002https://conductscience.org/library/papers/12111919PubMed
224033851Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.J Eur Acad Dermatol Venereol2014https://conductscience.org/library/papers/24033851PubMed
325455503Treatment goals for psoriasis: Should PASI 90 become the standard of care?Actas Dermosifiliogr2015https://conductscience.org/library/papers/25455503PubMed
421306785
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
J Am Acad Dermatol2011https://conductscience.org/library/papers/21306785PubMed
511781126A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis.J Clin Epidemiol2002https://conductscience.org/library/papers/11781126PubMed
615383414Bias due to aggregation of individual covariates in the Cox regression model.Am J Epidemiol2004https://conductscience.org/library/papers/15383414PubMed
715872205Psoriasis.N Engl J Med2005https://conductscience.org/library/papers/15872205PubMed
826149717Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.Br J Dermatol2015https://conductscience.org/library/papers/26149717PubMed
920358280Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation.J Pharmacokinet Pharmacodyn2010https://conductscience.org/library/papers/20358280PubMed
1026051365Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.Lancet2015https://conductscience.org/library/papers/26051365PubMed
1125418186Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.Br J Dermatol2015https://conductscience.org/library/papers/25418186PubMed

Download CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42692517Quantitative evaluations of time-course and effectiveness of systemic treatments for atopic dermatitis: protocol for a pharmacodynamic model-based meta-analysis.BMJ Open2026https://conductscience.org/library/papers/42692517PubMed
39245866Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis.Clin Pharmacol Ther2025https://conductscience.org/library/papers/39245866PubMed
36947282Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials.J Pharmacokinet Pharmacodyn2023https://conductscience.org/library/papers/36947282PubMed
35955723VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures.Int J Mol Sci2022https://conductscience.org/library/papers/35955723PubMed
35799700Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.Front Pediatr2022https://conductscience.org/library/papers/35799700PubMed
35174432Applications of Model-Based Meta-Analysis in Drug Development.Pharm Res2022https://conductscience.org/library/papers/35174432PubMed
34276352Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.Front Pharmacol2021https://conductscience.org/library/papers/34276352PubMed
31544068Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology.Indian Dermatol Online J2019https://conductscience.org/library/papers/31544068PubMed
31502263Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.Clin Pharmacol Ther2020https://conductscience.org/library/papers/31502263PubMed
31013000Modelling time-course relationships with multiple treatments: Model-based network meta-analysis for continuous summary outcomes.Res Synth Methods2019https://conductscience.org/library/papers/31013000PubMed
30188571Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.Br J Dermatol2019https://conductscience.org/library/papers/30188571PubMed
29569841Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal Responses.CPT Pharmacometrics Syst Pharmacol2018https://conductscience.org/library/papers/29569841PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD2914PubTator's text mininghttps://conductscience.org/library/genes/914NCBI Gene
IL17A3605PubTator's text mininghttps://conductscience.org/library/genes/3605NCBI Gene
PDE4A5141PubTator's text mininghttps://conductscience.org/library/genes/5141NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28480503

GET https://conductscience.org/api/papers/v1/28480503/authors